All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsSTANFORD UNIVERSITY

STANFORD UNIVERSITY

Projects attributed to STANFORD UNIVERSITY within this analysis sample.

In This Analysis
Projects
2
NIH Funding
$3.0M
Projects(2)
ProjectPICategoryFunding
Targeting apoptotic cells to enhance radiotherapy
4R01CA271530-04
RAO, JIANGHONGTherapeutics$1.7M
Development of a theragnostic radiopharmaceutical for pancreatic cancer
5R01CA289924-02
FERRARA, KATHERINE WBiotools$1.3M
See STANFORD UNIVERSITY’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.